CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 122 enrolled
Drug / intervention
fluticasone propionate/salmeterol combination DISKUSdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00269087
NCT00269087Phase 3Completed
CompareCT.gov

Clinical Evaluation of GW815SF for Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)" A Long-term Treatment Study of GW815SF50/500µg in Chronic Obstructive Pulmonary Disease -

GlaxoSmithKline·interventional·Posted Dec 23, 2005·Updated Feb 1, 2019

In Brief

A Phase 3 clinical trial evaluating fluticasone propionate/salmeterol combination DISKUS for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 122 participants across 5 sites.

Detailed Summary

This study evaluates the safety of medicine on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 56 weeks, and subjects will visit the clinic 16 times. Subjects will be given breathing tests, and will record their breathing symptoms daily on diary cards.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
Countries, Japan
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 23, 2005
Enrollment StartJan 28, 2005
Primary CompletionOct 1, 2006
Study CompletionOct 25, 2006
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 20.5 years ago

Interventions

fluticasone propionate/salmeterol combination DISKUSdrug